A significant increase in the expression of FA2G2S2 and A2G2S2 glycans was observed in RCC(-) samples, i.e., after nephrectomy of a localized tumor, whereas blood plasma samples of RCC(+) patients before nephrectomy were characterized by a significant decrease in FA2G2S2 and A2G2S(3)2 expression in clusterin glycans [115]. The gene discussed is CLU; the disease is renal cell carcinoma.